In vitro susceptibility study of Candida Spp. isolates to new combined potential medicinal product for the treatment of vaginal candidiasis
Journal Title: ScienceRise: Pharmaceutical Science - Year 2018, Vol 0, Issue 1
Abstract
<p>Research of the antimicrobial action of model specimens of a potential drug in various fixed combinations and the advent of specific antimycotic activity of model samples of a new, combined, potential drug and medicine product, selected as a reference "Neo-Penotran®" (Exeltis Healthcare S.L., Spain).</p><p><strong>Aim of the research</strong> was to determine the susceptibility of in vitro Candida spp. isolates to a new combined drug containing a substance with an antimycotic activity for the treatment of vaginal candidiasis.</p><p><strong>Materials and methods.</strong> Candida albicans (ATCC 10231) and Candida albicans (clinical isolate) from the material, urogenital pathways from women with a diagnosis of candidiasis were used to prove the activity and determine the sensitivity.</p><p>The study of antimicrobial activity was carried out using the serial dilutions method in trypticase-soybean broth, which allowed to ensure a uniform distribution of the drug in the nutrient medium in contact with pathogenic strains, and the subsequent transfer to Petri dishes on Sabouraud agar - the most accurate evaluation of the results.</p><p><strong>Results</strong> of the study of the antimycotic activity of 7 model specimens showed antimycotic activity in only 3 model specimens in relation to both the reference strain Candida albicans ATCC 10231 and the clinical strain of Candida albicans.</p><p><strong>Conclusions.</strong> The results of the studies indicate that there is a strong in vitro antimycotic effect of the new potential combined drug against pathogenic test strains: Candida albicans ATCC 10231, Candida albicans (clinical isolate), which is not inferior to the selected reference medicine. Minimum inhibitory concentration of the test drug in vitro was established for pathogenic test strains: Candida albicans ATCC 10231, Candida albicans (clinical isolate). The study of various combinations and concentrations of the combined drug made it possible to exclude the presence of negative interaction between components of the experimental specimen and to select the most promising and effective sample for further experimental studies of combinations of antimycotics for intravaginal use</p>
Authors and Affiliations
Iryna Nizhenkovska, Liudmyla Zinchenko
Keywords
Related Articles
- EP ID EP526815
- DOI 10.15587/2519-4852.2018.124534
- Views 213
- Downloads 0
The ointment containing Ag@Fe3O4 for removal and treatment of skin neoplasms
<p><strong>Aim. </strong>Priorities for improving the thermal conductivity values and the external controllability of the process of cryosurgical intervention have determined. The aim of this work is creation of soft dos...
Development of mask-cream technology with herbal substances for the androgenic alopecia treatment
Aim. The aim of the study was to develop a rational technology of mask-cream containing Sabal palm extract and Sophora japonica tincture applied for prevention and tratment of androgenic alopecia. Methods. Pharmaco-tech...
The analysis of the sale of antihypertensive drugs in the pharmacies of Kyiv
<p><strong>А</strong><strong>im.</strong> Antihypertensive drugs (AHD) belong to the category of the most commonly used drugs in the pharmaceutical market of Ukraine. This is due to the significant prevalence of arterial...
Оцінка однорідності гелю з екстрактів листя айви й шроту винограду на основі поліметилсилоксану з метою оптимізації та удосконалення технології
<p><strong>Мета. </strong>Оптимізування технології отримання гелю з екстрактами листя айви й шроту винограду на основі поліметилсилоксану для отримання якісного лікарського препарату з оптимальним терміном зберігання.</p...
Анализ ассортимента и доступности гепатотропных лекарственных средств на фармацевтическом рынке Украины
<p><strong>Цель работы:</strong> анализ ассортимента, потребления и социально-экономической доступности гепатотропных лекарственных средств (гепатопротекторов) на фармацевтическом рынке Украины за период 2012–2015 гг.</p...